Understanding how Epstein Barr virus causes lymphomas after organ transplants
Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
This study is looking at how the Epstein Barr virus can cause certain types of cancer in people who have had organ transplants, and it aims to find out how specific parts of the virus affect the immune system, which could help improve prevention and treatment for those patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10913587 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the Epstein Barr virus (EBV) leads to serious B cell lymphomas in individuals who have received solid organ transplants. The study focuses on understanding how specific viral genes, particularly the latent membrane protein 1 (LMP1), contribute to the development of post-transplant lymphoproliferative disease (PTLD). By analyzing samples from transplant recipients, the researchers aim to uncover the alterations in immune responses that predispose some patients to develop EBV-related lymphomas. This work could provide insights into better prevention and treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received solid organ transplants and are at risk for developing EBV-related lymphomas.
Not a fit: Patients who have not undergone solid organ transplantation or those without EBV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating lymphomas caused by Epstein Barr virus in transplant recipients.
How similar studies have performed: Previous studies have shown promising results in understanding the role of EBV in lymphomagenesis, indicating that this research builds on established findings.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Martinez, Olivia M — Stanford University
- Study coordinator: Martinez, Olivia M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.